# Cross-neutralization Capacity of Immune Serum From Different Dosage of Sabin Inactivated Poliovirus Vaccine Immunization

> **NCT04618783** · NA · COMPLETED · sponsor: **Sinovac Biotech Co., Ltd** · enrollment: 250 (actual)

## Conditions studied

- Poliomyelitis

## Interventions

- **BIOLOGICAL:** Three doses of low-dosage investigational sIPV, vaccinated within one-month interval between doses
- **BIOLOGICAL:** Three doses of medium-dosage investigational sIPV, vaccinated within one-month interval between doses
- **BIOLOGICAL:** Three doses of high-dosage investigational sIPV, vaccinated within one-month interval between doses
- **BIOLOGICAL:** Three doses of control wIPV, vaccinated within one-month interval between doses
- **BIOLOGICAL:** Three doses of control sIPV, vaccinated within one-month interval between doses

## Key facts

- **NCT ID:** NCT04618783
- **Lead sponsor:** Sinovac Biotech Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-07-20
- **Primary completion:** 2019-12-10
- **Final completion:** 2020-01-10
- **Target enrollment:** 250 (ACTUAL)
- **Last updated:** 2020-11-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04618783

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04618783, "Cross-neutralization Capacity of Immune Serum From Different Dosage of Sabin Inactivated Poliovirus Vaccine Immunization". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04618783. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*